Belgium (BE)

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer (2017) Fagerholm R, Khan S, Schmidt MK, Garcia-Closas M, Heikkila P, Saarela J, Beesley J, et al. Journal article Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation (2017) Hammer A, Schliep A, Joerg S, Haghikia A, Gold R, Kleinewietfeld M, Mueller DN, Linker R Journal article STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY (2017) Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Bello N, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution OPTIMAL DOSE OF TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: EFFICACY, SAFETY, AND EXPOSURE-EFFICACY ANALYSIS FROM GIACTA (2017) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Mallalieu NL, Aringer M, Blockmans D, et al. Conference contribution Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) (2017) Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, et al. Conference contribution Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline (2017) Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Lopez-Romero P, et al. Conference contribution European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes (2017) Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, et al. Journal article Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial (2017) Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, et al. Journal article